HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Luxury new energy vehicle (NEV) enterprise Seres officially released its 2025 annual results on March 30, with several core financial indicators recording steady growth and profitability continuing to strengthen for the second consecutive year, attracting widespread market attention.The results report shows that in 2025, Seres achieved revenue of approximately RMB164.89 billion with a year-on-year increase of 13.63%, net profit attributable to shareholders of the listed company was RMB5.96 billion and R&D investment reached RMB12.51 billion, a year-on-year increase of 77.4%. The Company also announced a proposed final dividend of RMB0.8 per share (tax included), totaling approximately RMB1.9 billion in cash dividends, reflecting its commitment to rewarding shareholders.In terms of sales performance, Seres' NEV sales continued to maintain a high level. Annual sales in 2025 reached 472,269 units, representing a year-on-year increase of 10.63%. The Group's premium brand AITO recorded cumulative annual deliveries exceeding 420,000 units, making it the best-selling Chinese luxury automotive brand in the domestic market. Across the full lineup, the AITO M5, M7, M8, and M9 collectively surpassed one million cumulative deliveries. The coordinated growth in both sales and profit further strengthened the Group's overall operational resilience and risk management capabilities.In terms of R&D investment, Seres has maintained a strong commitment. In 2025, the Company’s R&D investment reached RMB12.51 billion, representing a year-on-year increase of 77.4%. Both the intensity and growth rate of R&D investment remained industry-leading, reflecting the Company’s adherence to a technology-driven strategy and laying a solid foundation for future product iteration and core competitiveness.The Group’s cash flow performance was also robust. As of December 31, 2025, net cash flow from operating activities amounted to RMB28.12 billion. Ample cash reserves enabled the Company to support high-intensity R&D and international expansion while building a stronger risk buffer and enhancing strategic flexibility.Kaiyuan Securities, Changjiang Securities, CICC, and Guotai Haitong are among the major brokerages maintaining positive ratings on Seres — Kaiyuan and Changjiang with "Buy," Guotai Haitong with "Overweight," and CICC with "Outperform" alongside a revised target price of RMB 120. All institutions are optimistic on Seres' long-term growth prospects, noting that underlying business fundamentals continue to improve with a clear and compelling growth thesis. Key catalysts include a dense Q2 model launch cycle (AITO M6 and refreshed M9/M8), accelerating overseas expansion into the Middle East and Europe, and a robotics business increasingly seen as a credible second growth curve.Overall, Seres delivered a comprehensive upgrade in its 2025 results, spanning sales volume, profit, R&D and cash flow. The Company stated that it will continue to position itself as a luxury vehicle enterprise, deepen its presence in the intelligent NEV sector, further increase investment in core technologies, enrich its high-end product portfolio, accelerate its global market expansion, and focus on improving profitability and core competitiveness, thereby supporting the continued upgrading of China’s new energy vehicle industry. For investors, this performance has undoubtedly strengthened confidence in the Company’s future growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector’s future.A clear signal of the company’s growth arrived in February 2026, when HighTide Therapeutics (2511.HK) announced a high-profile executive appointment: Dr. Filip Surmont joined the company as Chief Medical Officer (CMO).For professionals in the cardiovascular, renal, and metabolic fields, this is a name that carries real weight. Over a career spanning three decades, Dr. Surmont has held senior medical leadership roles at multinational giants including Wyeth, Pfizer, and AstraZeneca. Among his most notable contributions was his role in the global strategic development of the SGLT-2 inhibitor dapagliflozin — a landmark effort that required close collaboration across functions and geographies within a large multinational organization. As part of a talented cross-functional team, he helped shape the strategy that positioned dapagliflozin as a global metabolic blockbuster, ultimately reaching $8.405 billion USD in sales in 2025.Notably, just a few months earlier, HighTide Therapeutics' core product, HTD1801, had outperformed dapagliflozin across multiple key cardiovascular, renal, and metabolic endpoints in a head-to-head Phase III clinical trial for type 2 diabetes mellitus (T2DM).For Dr. Surmont, transitioning from managing a reigning "blockbuster" to joining a “challenger” Chinese biotech was far from coincidental. What drew him out of his comfort zone was not just HTD1801's strong glucose-lowering performance, but also the breakthrough potential this new molecular entity (NME) has shown in cardiovascular, kidney and metabolic (CKM) disease in general, and chronic kidney disease (CKD) more specifically — driven by a fundamentally differentiated pathophysiological mechanisms.I.Challenging Clinical Complacency in CKD: The Quest for True ReversalWithin the medical community, chronic kidney disease (CKD) has long been a source of frustration. Once the kidney function begins to decline, it typically deteriorates progressively and irreversibly over time, leaving most patients facing dialysis or kidney transplantation as an eventual outcome."There has long been a degree of complacency in CKD treatment among physicians, patients, and even caregivers," Dr. Surmont noted pointedly. "A mindset has taken hold that the progressive decline in renal function with age is inevitable. I’ve been striving to change this mindset throughout my career, both during my time at multinational pharmaceutical companies and now."Current standard treatments — including ACE inhibitors/ARBs and the widely used SGLT-2 inhibitors — have demonstrated efficacy in slowing disease progression, yet fall short of halting or reversing the underlying pathology. They can significantly reduce the rate of decline in the estimated glomerular filtration rate (eGFR), buying patients valuable time, but fail to alter the terminal trajectory towards kidney failure.Further complicating the clinical picture is the multi-factorial nature of CKD. Taking diabetic kidney disease (DKD) caused by T2DM as an example, besides pathophysiological factors driven by metabolic dysfunction, it is complicated by interconnected and highly complex factors such as hemodynamic perturbances, chronic inflammation, fibrosis, and other non-diabetic factors that fuel each other to worsen disease prognosis.Existing standard-of-care drugs often address only one dimension of the disease by regulating hemodynamics or a single metabolic pathway, making it difficult to comprehensively address the inflammatory damage in the renal microenvironment.II.Inside the Mechanism: Remodeling Renal Architecture via a Dual Metabolic and Anti-inflammatory PathwayThe emergence of HTD1801 provides a new key to breaking this deadlock.As an oral anti-inflammatory and metabolic modulator (AIMM) independently developed by HighTide Therapeutics, HTD1801 demonstrates a unique therapeutic potential at the microscopic level as compared to traditional drugs. Rather than relying on a single mechanism, it takes a "two-pronged" approach by activating AMPK (adenosine monophosphate-activated protein kinase) and inhibiting the NLRP3 inflammasome.Dr. Surmont has full confidence in the scientific logic underpinning this mechanism: "This drug acts simultaneously on two critical levels: beyond blood sugar, it improves overall metabolic efficiency at its source; at the same time, it directly suppresses the underlying chronic inflammation that drives organ damage."Taking a deep dive into its mechanism of action, HTD1801's dual mechanism precisely targets multiple microstructures within the kidney. "This is reflected across different renal compartments," Dr. Surmont explained. "From the filtering glomeruli and the structural interstitium to the reabsorptive tubules, and even podocytes—the vital gatekeepers of the filtration barrier, the dual action of AMPK activation and NLRP3 inhibition has demonstrated stronger-than-expected protective benefits."This mechanistic rationale, spanning from metabolic regulation to organ-level protection, has ultimately been validated by clinical data.At the 2025 American Society of Nephrology (ASN) Annual Meeting, HighTide Therapeutics presented as a late breaker Phase III clinical study data in T2DM patients with mild renal impairment. The results captured the industry's attention: compared with the placebo group, the HTD1801 group demonstrated a significant and sustainable difference in annualized eGFR slope of +9.81 ml/min/1.73 m²/year.In the eyes of nephrologists, a "positive slope" on the eGFR curve is a strong and unique signal, suggesting the possibility of early structural recovery."What we need to do next is confirm that this eGFR repair effect observed in DKD also holds true for CKD patients not driven by diabetes," Dr. Surmont revealed, indicating that relevant clinical studies are already underway, with more detailed data expected to validate this cross-etiology therapeutic potential.III.From "Rescue" to "Prevention": Advancing a Holistic Cardiorenal Metabolic (CKM) MindsetDr. Surmont brings to HighTide Therapeutics more than just clinical expertise; he brings a “game-changing” mentality that transcends a single-drug perspective.Another career-defining milestone for Dr. Surmont was his leadership role in helping reshape global asthma treatment guidelines. Historically, asthma management relied on short-acting bronchodilators for "rescue" only upon exacerbation of symptoms and shortness of breath. Dr. Surmont proposed and validated the "Anti-Inflammatory Reliever (AIR)" strategy a modern asthma management strategy that uses a combination inhaled corticosteroids and a bronchodilator as a reliever — treating both the acute bronchospasm and the underlying airway inflammation with every dose, in contrast to traditional short acting dilator-only relief.  This shift ultimately benefited approximately 120 million patients worldwide and reshaped treatment paradigms.Now, facing CKD, he sees the same opportunity for a paradigm-shifting breakthrough.Given HTD1801's strong potential to repair mild renal impairment, future clinical guidelines could reasonably recommend initiating treatments early, when eGFR is still at a relatively high level. By establishing a positive trajectory for renal function recovery early in the disease, there is hope that most patients can completely avoid the looming threat of dialysis.From a health-economics perspective, this would reallocate healthcare spending: shifting funds away from costly late-stage interventions (such as dialysis and heart failure rescue) towards highly cost-effective early treatment, thereby generating substantial healthcare cost savings for society and reducing patients’ financial burden for late-stage interventions.Dr. Surmont also strongly advocates for a holistic management approach to "Cardiovascular-Kidney-Metabolic (CKM)" health. As multifunctional drugs like HTD1801 continue to evolve, he believes physicians will move beyond the single-dimensional therapeutic mindset."My ideal scenario is that all physicians managing cardiovascular, metabolic, renal, hepatic, or even obesity issues would evaluate the patient with a holistic mindset," he says, pointing to the current siloed nature in clinical practice. " As an example eGFR monitoring is not always part of routine cardiological assessment, yet at the mechanistic level, cardiac and renal dysfunction are manifestations of the same underlying disease process — making an integrated view essential"He cited a successful experiment he led while promoting dapagliflozin in China: requiring cardiologists at partner hospitals to measure patients' eGFR during their consultations. By merely adding this simple cross-disciplinary action, the number of patients on guideline directed medical treatment tripled within six months.IV.A Buyer's Lens: The Booming BD Activity in CKD and HighTide Therapeutics’ Confidence in Value CreationAs a core member of the company's leadership team, Dr. Surmont also frequently examines HighTide Therapeutics' position through the lens of capital market and industry dynamics.Over the past two years, the global biopharmaceutical market has seen a surge in business development (BD) activity in the CKD field. In 2025, Roche announced a major collaboration with Zealand Pharma valued at up to $5.3 billion; multinational giants like Novartis, Boehringer Ingelheim, and Novo Nordisk have also been making significant investments to secure premium assets in the metabolic and renal disease space.Dr. Surmont, drawing on his extensive multinational experience, has a clear read on this "land grab" phenomenon: "The core driver is the massive profit potential and rapid growth in this field. Five years ago, the therapeutic arsenal here was relatively limited. Now, with breakthrough blockbusters like GLP-1RAs and SGLT-2i’s, the kidney disease landscape has been reshaped, yet there remains a residual risk is 60–80% of the original event burden.He further elaborated: "Even when patients are treated with four pillars of therapy (ACEi/ARBs, SGLT-2i’s, GLP-1RAs, MRAs), the complex underlying inflammatory mechanisms remain largely unaddressed, still leaving a significant gap in our ability to fully protect the kidney. This creates substantial pricing potential and broad combination therapy prospects for drugs with fundamentally new mechanisms like HTD1801.""Looking back at the history of SGLT-2 inhibitors, it took over a decade from approval to reaching 20%-25% guideline-directed clinical uptake. The slow progress was partly due to a lack of strong medical education and advocacy, and partly because of physicians and patients’ tendency to yield to the disease's natural trajectory."Now, having taken the helm as CMO of HighTide Therapeutics, Dr. Filip Surmont is poised to challenge the status quo and break this complacency with solid clinical data and a new medical narrative. For this drug—born from Chinese innovation with a global ambition—the voyage in the CKM field has only just begun. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TransNusa Launches New Scheduled Flight Connecting Jakarta With Lombok, Its World Class Surfing Island DestinationJAKARTA, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - TransNusa has announced the launch of a new direct scheduled flight connecting Jakarta and Lombok, further strengthening access to one of Indonesia’s key tourism and regional travel hubs.TransNusa Airlines Group Chief Executive Officer, Datuk Bernard Francis said that the introduction of this new route comes on the back of the airline’s focus to increase and strengthen connectivity while boosting domestic tourism.“Lombok is not only rapidly growing as a domestic and international tourist destination but the island is also the main gateway for tourism in the West Nusa Tenggara region through its Lombok International Airport,” Datuk Francis said, adding that Lombok attracts more than 1.2 million tourists annually.LOMBOK… Paradise of divers and surfersLombok is home to the diving haven Gili and Mount Rinjani National Park, one of Indonesia’s most iconic volcanic landscapes. The island offers dramatic trekking routes, cascading waterfalls and panoramic mountain views, attracting adventurers and nature lovers from around the world. Beyond its mountains, Lombok has also built a global reputation as a world-class surfing and diving destination, with pristine beaches, coral reef and consistent waves drawing surfers year-round.“TransNusa will initially operate 14 flights a week or two daily flights with the first scheduled flight departing Jakarta in the morning and the second in the afternoon,” Datuk Bernard said, adding that the sales of tickets for the new scheduled flight from Jakarta to Lombok started on 16 March 2026, with the inaugural flight scheduled for April 17, 2026.DATUK BERNARD FRANCIS… Lombok is the main gateway for tourism in the West Nusa Tenggara regionIn addition to this new launch, TransNusa has also increased the frequency of its Jakarta-Yogyakarta route with the aim to enhance and strengthen domestic connectivity, said Datuk Bernard.Flight DetailsTransNusa’s scheduled flight 8B 5161 will depart Soekarno–Hatta International Airport at 5:00am and arrive at Lombok International Airport at 8:00am. The returning service, 8B 5162, will depart Lombok International Airport at 8:30am and arrive in Jakarta at the Soekarno–Hatta International Airport at 9:30am. The second scheduled flight 8B 5165 will depart Jakarta’s Soekarno–Hatta International Airport at 03:00pm and arrive at the Lombok International Airport at 05:45pm. The returning service, 8B 5166 will depart Lombok International Airport at 06.15pm and arrive at the Soekarno–Hatta International Airport at 06.45pm.Ticket prices for TransNusa’s scheduled Jakarta-Lombok route start from as low as IDR899,000, CNY390, USD55, MYR225, AUD80, and SGD69. Tickets will be available for purchase at www.transnusa.co.id and on primary online travel agents’ platforms.Meanwhile, TransNusa’s additional scheduled flight for its Jakarta-Yogyakarta flight, 8B 5530, will depart Jakarta’s Soekarno–Hatta International Airport at 10.40am and arrive at the Yogyakarta International Airport at 11.50am. The flight, 8B 5531, will depart Yogyakarta at 01.20pm and arrive in Jakarta at 02.30pm.For its flights, TransNusa not only provides premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our SEAT passengers will enjoy check-in baggage of up to 20kgs,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.For the highest package, FLEXI-PRO, we provide services such as free baggage up to 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding counters.In addition, TransNusa also provides its FLEXI-PRO passengers with the flexibility to change their flight schedule without restrictions and obtain refund when needed,” added Datuk Bernard.TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” stressed Datuk Bernard.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.About TransNusaTransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022.In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali.On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Perth, Shanghai, and Shenzhen. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia.TransNusa’s Primary International Media Contact:Trina Thomas Rajtrina@myqaseh.org+60124992672 (whatsapp only) Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 2, 2026 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings’ (0697.HK) investments in the robotics sector are moving from early-stage positioning toward value realization.Management has disclosed that, by the end of 2025, the Company—through multiple industry funds under its management—had cumulatively invested more than RMB 2 billion across the broader robotics industry chain, covering more than 20 companies. According to the Chairman’s Statement for 2025, the valuation of the investment portfolio of the Beijing Robot Industry Development Investment Fund (Limited Partnership) increased by approximately fourfold. On that basis, the corresponding unrealized book gain is estimated at around RMB 8 billion. The robotics business has therefore become one of the most closely watched sources of incremental upside for Shoucheng Holdings in the near term.Based on disclosed projects, Shoucheng Holdings’ robotics strategy is not a series of isolated bets, but rather a systematic deployment across the industry chain. In the field of embodied intelligence and robotics, the Company has made concentrated investments in more than 20 leading companies, including Unitree Robotics, Noetix Robotics, Galbot, DEEP Robotics, Booster Robotics, and Galaxea AI. In the latest Chairman’s Statement, Chairman Zhao Tianyang characterized this approach as “track-level deployment”.Unlike some purely financial investors, Shoucheng Holdings is advancing its robotics business from simply “holding equity stakes” to “operating an industry”. Following an integrated path of “investment + operations + ecosystem,” the Company is building capabilities centered on “funds + scenarios + industry chain,” providing robotics companies with capital support, application scenarios, supply-chain integration, and commercialization pathways. On the offline channel side, its robotics consumer experience brand, Taozhu New Creation, has established five stores in Beijing, with locations including Shougang Park, Beijing Capital International Airport Terminals 2 and 3, and Wangfujing APM, among other core venues. To date, the Company has signed agreements with nearly 100 robotics companies as authorized agents.Market analysts note that the valuation logic for Shoucheng Holdings’ robotics business is transitioning from book valuations in the primary market toward more observable pricing in the capital markets. As a representative investment within Shoucheng Holdings’ robotics portfolio, Unitree Robotics—together with its IPO progress—provides the market with a clearer anchor for assessing the value of Shoucheng Holdings’ robotics assets.From a longer-term perspective, the data points of “more than RMB 2 billion invested, more than 20 companies covered, and portfolio valuation increasing approximately fourfold to around RMB 8 billion” already outline the basic contours of Shoucheng Holdings’ robotics strategy:At the front end, the Company secures leading projects through its funds.In the mid-stage, it accelerates commercialization through channels and service systems.At the back end, it opens up exit and re-rating opportunities through IPOs and capital operations.As projects such as Unitree Robotics move into the capital-market spotlight, the book value of Shoucheng Holdings’ robotics investments, its industrial synergy capabilities, and its subsequent monetization path are becoming increasingly clear. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com